Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by NewLink Genetics Corporation
Sponsor:
Information provided by (Responsible Party):
NewLink Genetics Corporation
ClinicalTrials.gov Identifier:
NCT01836432
First received: April 17, 2013
Last updated: July 1, 2014
Last verified: July 2014
  Purpose

Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease. One primary reason for this is that the disease is typically without symptoms until significant local and/or distant spread has occurred and is often beyond the chance for cure at the time of the diagnosis. The lack of any treatment to substantially increase long term survival rates is reflected by the poor outcomes associated with this disease, specifically time to disease progression and overall survival.

However, another important part of the body is now being looked at as a target for therapy against this disease - the immune system. Scientists have clearly shown that pancreatic tumor cells produce a number of defective proteins, or express normal proteins in highly uncharacteristic ways, as part of this cancer. In some cancers, these abnormalities can cause an immune response to the cancer cells much in the way one responds to infected tissue. In progressive cancers however, the immune system fails to effectively identify or respond to these abnormalities and the cancer cells are not attacked or destroyed for reasons not yet fully understood. This clinical trial proposes a new way to stimulate the immune system to recognize pancreatic cancer cells and to stimulate an immune response that destroys or blocks the growth of the cancer.

This new method of treatment helps the immune system of pancreatic cancer patients to "identify" the cancerous tissue so that it can be eliminated from the body. As an example, most people are aware that patients with certain diseases may require an organ transplant to replace a damaged kidney or heart. After receiving their transplant, these patients receive special drugs because they are at great danger of having an immune response that destroys or "rejects" the transplanted organ. This "rejection" occurs when their immune system responds to differences between the cells of the transplanted organ and their own immune system by attacking the foreign tissue in the same way as it would attack infected tissue. When the differences between foreign tissues and the patient's body are even larger, as with the differences between organs from different species, the rejection is very rapid, highly destructive, and the immunity it generates is longlasting. This is called hyperacute rejection and the medicine used to immunize patients in this protocol tries to harness this response to teach a patient's immune system to fight their pancreatic cancer just as the body would learn to reject a transplanted organ from an animal.

To do this, Algenpantucel-L immunotherapy contains human pancreatic cancer cells that contain a mouse gene that marks the cancer cells as foreign to patient's immune systems. The immune system therefore attacks these cancer cells just as they would attack any truly foreign tissue, destroying as much as it can. Additionally, the immune system is stimulated to identify differences (aside from the mouse gene) between these cancer cells and normal human tissue as foreign. This "education" of the immune system helps treat the patient because pancreatic cancer cells already present in a treated patient are believed to show some of the same differences from normal tissue as the modified pancreatic cancer cells in the product. Due to these similarities, the immune system, once "educated" by the Algenpantucel-L immunotherapy, identifies the patient's cancer as foreign and attacks.

The chemotherapy combination to be used in this study has been shown to improve survival in advanced pancreatic cancer and is being combined with an experimental pancreatic cancer immunotherapy that stimulates the immune system to recognize and attack the cancer. One goal of this study is to determine whether chemotherapy and immunotherapies can work cooperatively to increase anti-tumor effects to levels beyond what would be seen with either treatment alone.

In this experimental study, all patients are given a strong combination of anti-tumor chemotherapies while some patients are also given injections of an immunotherapy drug consisting of two types of pancreatic cancer cells that we have modified to make them more easily recognized and attacked by the immune system. We propose to test this new treatment protocol in patients with locally advanced pancreatic cancer to demonstrate that treatment with the immunotherapy increases the time until the tumor progresses or increases overall survival when given in combination with the current standard of care therapy for this disease.


Condition Intervention Phase
Pancreatic Cancer
Pancreatic Carcinoma Non-resectable
Locally Advanced Malignant Neoplasm
Drug: FOLFIRINOX
Biological: Algenpantucel-L Immunotherapy
Radiation: 5-FU Chemoradiation
Drug: Gemcitabine
Drug: Capecitabine
Drug: Nab-Paclitaxel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Resource links provided by NLM:


Further study details as provided by NewLink Genetics Corporation:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: 13.5 months (assuming enrollment period of 1-2 years) ] [ Designated as safety issue: No ]
    The primary objective of this study is to assess overall survival (OS) in pancreatic cancer patients with borderline resectable or locally advanced unresectable pancreatic cancer who will receive a regimen of FOLFIRINOX or gemcitabine/nab-paclitaxel with or without algenpantucel-L Immunotherapy.


Secondary Outcome Measures:
  • Progression Free Survival [ Time Frame: 13.5 months (assuming enrollment period of 1-2 years) ] [ Designated as safety issue: No ]
    A secondary objective of this study is to assess progression free survival after treatment with a regimen of FOLFIRINOX or gemcitabine/nab-paclitaxel with or without algenpantucel-L immunotherapy in subjects who have borderline resectable or locally advanced pancreatic cancer.

  • Frequency and grade of adverse events of FOLFIRINOX or gemcitabine/nab-paclitaxel in combination with algenpantucel-L Immunotherapy versus FOLFIRINOX or gemcitabine/nab-paclitaxel alone [ Time Frame: 13.5 months (assuming enrollment period of 1-2 years) ] [ Designated as safety issue: Yes ]
    A secondary objective of this study is to assess the safety (frequency and grade of adverse events) of administration of algenpantucel-L Immunotherapy given in combination with a standard of care regimen of chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel, to be referred to as standard of care, or SOC).

  • Immune Response [ Time Frame: 13.5 months (assuming enrollment period of 1-2 years) ] [ Designated as safety issue: No ]
    A secondary objective of this study is to assess the immunologic responses of subjects with pancreatic cancer undergoing antitumor immunization with algenpantucel-L Immunotherapy as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.


Estimated Enrollment: 280
Study Start Date: April 2013
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy

Arm 1A: SOC FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy

Day 71-80 Disease evaluated: New distant disease = salvage regimen Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.

Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation+ HAPa on days 1 and 15 of Chemoradiotherapy.

Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for up to 18 doses total.

Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue FOLFIRINOX bi-weekly + HAPa bi-weekly 7 days offset from FOLFIRINOX up to18 doses of algenpantucel-L Immunotherapy.

Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.

Drug: FOLFIRINOX

FOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours - given on days 22, 36, 50, and 64 for Arm 1A. FOLFIRINOX given on days 1, 15, 29, 43 and 57 for Arm 2A.

For arms 1B and 2B patients with disease progression at day 71-80 evaluation will receive FOLFIRINOX as noted above on a biweekly basis.

For arms 1A and 2A patients with stable disease after surgical resection will continue to receive FOLFIRINOX as noted above on a biweekly basis.

For arms 1B and 2B patients deemed ineligible for surgical resection with noted disease progression will be given FOLFIRINOX as noted above on a biweekly basis.

Other Names:
  • Oxaliplatin
  • Eloxatin®
  • Irinotecan
  • Camptosar®
  • Leucovorin
  • Citrovorum factor
  • folinic acid
  • Fluorouracil
  • 5-Fluorouracil
  • 5-FU
Biological: Algenpantucel-L Immunotherapy

HAPa1 and HAPa2 immunotherapy components Arm 1 (1A and 1B) only: Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection on days 1, 8, 15, 29, 43 and 57.

Patients receiving chemoradiation with HAPa will receive HAPa on days 1 and 15 of the 5.5 week 5-FU chemoradiation cycle.

Patients receiving continuation or salvage FOLFIRINOX with HAPa will receive HAPa biweekly, 7 days offset from the administration of FOLFIRNOX for up to 18 doses total.

Patients receiving adjuvant gemcitabine therapy with HAPa will receive HAPa on days 1 and 15 of each cycle for 5 cycles for up to 18 doses total.

Patients receiving continuation or salvage gemcitabine/nab-paclitaxel with HAPa will receive HAPa on days 8 and 22 (of each cycle) for up to 18 doses total.

Other Names:
  • HyperAcute®-Pancreas
  • HAPa
Radiation: 5-FU Chemoradiation
All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
Other Names:
  • Fluorouracil
  • 5-Fluorouracil
  • 5-FU
Drug: Gemcitabine

Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.

All Arms: Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles for all arms after surgical resection.

Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.

Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Other Name: Gemzar
Drug: Capecitabine
All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive capecitabine in place of 5-FU during radiation. Capecitabine consisting of 825 mg/m^2 PO BID M-F concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
Other Name: Xeloda
Drug: Nab-Paclitaxel

Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes (followed by Gemcitabine)

Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.

Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Other Names:
  • Abraxane
  • Paclitaxel
Active Comparator: FOLFIRINOX (SOC) ALONE

Arm 2A: FOLFIRINOX (Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours) given days 1, 15, 29, 43 & 57

Day 71-80 Disease eval: New disease = salvage Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest

Day 71-80 Disease eval: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy

Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine

Ineligible for surgical resection & stable disease = continue FOLFIRINOX

Ineligible for surgical resection & progressive disease = salvage Gem/Nab-Paclitaxel

Drug: FOLFIRINOX

FOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours - given on days 22, 36, 50, and 64 for Arm 1A. FOLFIRINOX given on days 1, 15, 29, 43 and 57 for Arm 2A.

For arms 1B and 2B patients with disease progression at day 71-80 evaluation will receive FOLFIRINOX as noted above on a biweekly basis.

For arms 1A and 2A patients with stable disease after surgical resection will continue to receive FOLFIRINOX as noted above on a biweekly basis.

For arms 1B and 2B patients deemed ineligible for surgical resection with noted disease progression will be given FOLFIRINOX as noted above on a biweekly basis.

Other Names:
  • Oxaliplatin
  • Eloxatin®
  • Irinotecan
  • Camptosar®
  • Leucovorin
  • Citrovorum factor
  • folinic acid
  • Fluorouracil
  • 5-Fluorouracil
  • 5-FU
Radiation: 5-FU Chemoradiation
All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
Other Names:
  • Fluorouracil
  • 5-Fluorouracil
  • 5-FU
Drug: Gemcitabine

Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.

All Arms: Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles for all arms after surgical resection.

Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.

Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Other Name: Gemzar
Drug: Capecitabine
All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive capecitabine in place of 5-FU during radiation. Capecitabine consisting of 825 mg/m^2 PO BID M-F concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
Other Name: Xeloda
Drug: Nab-Paclitaxel

Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes (followed by Gemcitabine)

Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.

Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Other Names:
  • Abraxane
  • Paclitaxel
Experimental: Gemcitabine/Nab-Paclitaxel+Algenpantucel-L HAPa Immunotherapy

Arm 1B: Gemcitabine/Nab-Paclitaxel + Algenpantucel-L (HAPa) Immunotherapy

Day 71-80 Disease evaluated: New distant disease = salvage regimen FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.

Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation + HAPa on days 1 and 15 of Chemoradiotherapy.

Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given days 1 and 15 for up to 18 doses total.

Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue Gem/Nab-Paclitaxel + HAPa given on days 8 and 22 for up to18 doses of algenpantucel-L Immunotherapy.

Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.

Drug: FOLFIRINOX

FOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours - given on days 22, 36, 50, and 64 for Arm 1A. FOLFIRINOX given on days 1, 15, 29, 43 and 57 for Arm 2A.

For arms 1B and 2B patients with disease progression at day 71-80 evaluation will receive FOLFIRINOX as noted above on a biweekly basis.

For arms 1A and 2A patients with stable disease after surgical resection will continue to receive FOLFIRINOX as noted above on a biweekly basis.

For arms 1B and 2B patients deemed ineligible for surgical resection with noted disease progression will be given FOLFIRINOX as noted above on a biweekly basis.

Other Names:
  • Oxaliplatin
  • Eloxatin®
  • Irinotecan
  • Camptosar®
  • Leucovorin
  • Citrovorum factor
  • folinic acid
  • Fluorouracil
  • 5-Fluorouracil
  • 5-FU
Biological: Algenpantucel-L Immunotherapy

HAPa1 and HAPa2 immunotherapy components Arm 1 (1A and 1B) only: Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection on days 1, 8, 15, 29, 43 and 57.

Patients receiving chemoradiation with HAPa will receive HAPa on days 1 and 15 of the 5.5 week 5-FU chemoradiation cycle.

Patients receiving continuation or salvage FOLFIRINOX with HAPa will receive HAPa biweekly, 7 days offset from the administration of FOLFIRNOX for up to 18 doses total.

Patients receiving adjuvant gemcitabine therapy with HAPa will receive HAPa on days 1 and 15 of each cycle for 5 cycles for up to 18 doses total.

Patients receiving continuation or salvage gemcitabine/nab-paclitaxel with HAPa will receive HAPa on days 8 and 22 (of each cycle) for up to 18 doses total.

Other Names:
  • HyperAcute®-Pancreas
  • HAPa
Radiation: 5-FU Chemoradiation
All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
Other Names:
  • Fluorouracil
  • 5-Fluorouracil
  • 5-FU
Drug: Gemcitabine

Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.

All Arms: Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles for all arms after surgical resection.

Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.

Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Other Name: Gemzar
Drug: Capecitabine
All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive capecitabine in place of 5-FU during radiation. Capecitabine consisting of 825 mg/m^2 PO BID M-F concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
Other Name: Xeloda
Drug: Nab-Paclitaxel

Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes (followed by Gemcitabine)

Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.

Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Other Names:
  • Abraxane
  • Paclitaxel
Active Comparator: Gemcitabine/Nab-Paclitaxel (SOC) Alone

Arm 2B: Gemcitabine/Nab-Paclitaxel (SOC) Alone

SOC Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks with 1 week rest. Given on days 1, 8, 15, 29, 36, 43, 57, 64 and 71

Day 71-80 Disease evaluated: New distant disease = salvage FOLFIRINOX given every 14 days

Day 71-80 Disease evaluation: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy

Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine

Ineligible for surgical resection & stable disease = continue gem/nab-paclitaxel given for 3 weeks (days 1, 8 and 15) with 1 week rest

Ineligible for surgical resection & progressive disease = salvage FOLFIRINOX given every 14 days

Drug: FOLFIRINOX

FOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours - given on days 22, 36, 50, and 64 for Arm 1A. FOLFIRINOX given on days 1, 15, 29, 43 and 57 for Arm 2A.

For arms 1B and 2B patients with disease progression at day 71-80 evaluation will receive FOLFIRINOX as noted above on a biweekly basis.

For arms 1A and 2A patients with stable disease after surgical resection will continue to receive FOLFIRINOX as noted above on a biweekly basis.

For arms 1B and 2B patients deemed ineligible for surgical resection with noted disease progression will be given FOLFIRINOX as noted above on a biweekly basis.

Other Names:
  • Oxaliplatin
  • Eloxatin®
  • Irinotecan
  • Camptosar®
  • Leucovorin
  • Citrovorum factor
  • folinic acid
  • Fluorouracil
  • 5-Fluorouracil
  • 5-FU
Radiation: 5-FU Chemoradiation
All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
Other Names:
  • Fluorouracil
  • 5-Fluorouracil
  • 5-FU
Drug: Gemcitabine

Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.

All Arms: Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles for all arms after surgical resection.

Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.

Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Other Name: Gemzar
Drug: Capecitabine
All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive capecitabine in place of 5-FU during radiation. Capecitabine consisting of 825 mg/m^2 PO BID M-F concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
Other Name: Xeloda
Drug: Nab-Paclitaxel

Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes (followed by Gemcitabine)

Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.

Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.

Other Names:
  • Abraxane
  • Paclitaxel

Detailed Description:

This protocol attempts to treat pancreatic cancer therapy using a naturally occurring barrier to xenotransplantation in humans to increase the efficacy of immunizing patients against their pancreatic cancer. In this protocol, the transfer of the murine α(1,3) galactosyltransferase [α(1,3)GT] gene to immunotherapy component cells results in the cell surface expression of α(1,3)galactosyl-epitopes (αgal) epitopes on membrane glycoproteins and glycolipids. These epitopes are the major target of the hyperacute rejection response. This response occurs when organs are transplanted from lower animal donor species into primates and results in rapid destruction of transplanted tissue and an augmented response against transplant antigens, including antigens not related to the αgal epitopes. Human hosts have pre-existing anti-α-gal antibodies that are thought to result from chronic immunological stimulation due to exposure to α-gal epitopes that are naturally expressed on normal gut flora and these antibodies may comprise up to 1% of serum immunoglobulin G (IgG). Opsonization and lysis of the immunotherapy component cells mediated by this antibody is believed to increase the efficiency of antigen processing by targeting vaccine components to antigen presenting cells via the Fcγ receptor.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A histological diagnosis of adenocarcinoma of the pancreas confirmed by pathology.
  • Patients must have borderline resectable or locally advanced unresectable pancreatic cancer with no metastatic spread as determined by a baseline diagnostic CT scan with intravenous contrast (or MRI). CT should be performed according to a defined pancreas protocol such as triphasic cross-sectional imaging with thin slices. Optimal multi-phase technique including a non-contrast phase plus arterial, pancreatic parenchymal and portal venous phase of contrast enhancement with thin cuts (3mm) throughout the abdomen is preferred. Studies must be evaluated by a radiologist and/or surgeon and deemed borderline resectable or locally advanced unresectable as defined per the NCCN Practice Guidelines in Oncology V2.2012, as:
  • Borderline resectable- Tumors considered borderline resectable are defined as follows:

    1. No distant metastases
    2. Venous involvement of the SMV/portal vein demonstrating tumor abutment with impingement and narrowing of the lumen, encasement of the SMV/portal vein but without encasement of the nearby arteries, or short-segment venous occlusion resulting from either tumor thrombus or encasement but with suitable vessel proximal and distal to the area of vessel involvement, allowing for safe resection and reconstruction
    3. Gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct abutment of the hepatic artery without extension to the celiac axis.
    4. Tumor abutment of the SMA not to exceed greater than 180 degrees of the circumference of the vessel wall.
  • Tumors considered to be unresectable due to local advancement include an absence of distant metastases as well as:

    1. Head: Greater than 180 degrees SMA encasement or any celiac abutment or unreconstructible SMV/portal occlusion or aortic invasion or encasement.
    2. Body: Greater than 180 degrees SMA or celiac encasement or unreconstructible SMV/portal occlusion or aortic invasion.
    3. Tail: SMA or celiac encasement greater than 180 degrees.
    4. Nodal status: Involvement of lymph nodes beyond the field of resection should be considered unresectable due to distant spread and therefore not eligible for this protocol.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
  • Serum albumin ≥ 2.0 gm/dL.
  • Expected survival ≥ 6 months.
  • Adequate organ function including:

    1. Marrow: WBC ≥3000/mm^3 and platelets ≥100,000/mm^3.
    2. Hepatic: serum total bilirubin ≤ 1.5 mg/dL, ALT (SGPT) and AST (SGOT) ≤3 x upper limit of normal (ULN) at time of enrollment. If a patient has elevated liver function tests at the time of initial presentation or develops them during work-up and they are the result of a mechanical obstruction of biliary drainage by tumor compression or invasion, a biliary drain may be placed as described in NCCN Practice Guidelines in Oncology V2.2012. If drainage allows for the liver function tests to come within inclusion criteria, the patient may be enrolled.
    3. Renal: serum creatinine (sCr) ≤2.0 x ULN, or creatinine clearance (Ccr) ≥30 mL/min.
  • Patients must have the ability to understand the study, its inherent risks, side effects and potential benefits and be able to give written informed consent to participate. Patients may not be consented by a durable power of attorney (DPA).
  • All subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product, and for one month after the last immunization.

Exclusion Criteria:

  • Age <18-years-old.
  • Active metastases.
  • Other malignancy within five years, unless the probability of recurrence of the prior malignancy is <5% as determined by the Principal Investigator based on available information. Patient's curatively treated for squamous and basal cell carcinoma of the skin or patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.
  • History of organ transplant.
  • Current, active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.
  • Subjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics per the FOLFIRINOX or gemcitabine/nab-paclitaxel regimen. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning treatment, will be removed from study.
  • Significant or uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias within the last six months.
  • Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  • Autoimmune disease (e.g., systemic lupus erythematosis (SLE), rheumatoid arthritis (RA), etc.). Patients with a remote history of asthma or mild active asthma are eligible.
  • Other serious medical conditions that may be expected to limit life expectancy to less than 2 years (e.g., active liver cirrhosis) or a serious illness in medical opinion of the clinical investigator.
  • Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.).
  • A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.
  • Pregnant or nursing women due to the unknown effects of immunization on the developing fetus or newborn infant. (For patients with child bearing potential, a βHCG must be completed within 14 days of first treatment).
  • Known HIV positive.
  • Prior treatment with chemotherapy or radiation for pancreatic cancer or prior treatment with radiation for other diagnoses to expected pancreatic cancer treatment fields.
  • Current grade II or higher peripheral neuropathy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01836432

  Hide Study Locations
Locations
United States, Arizona
Arizona Cancer Center Recruiting
Tucson, Arizona, United States, 85719
Contact: Laura Pestana    520-694-9060    lpestana@uacc.arizona.edu   
Principal Investigator: Emad Elquza, MD         
United States, California
City of Hope National Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Jaclyn Hiett    626-256-4673 ext 63113    jhiett@coh.org   
Principal Investigator: Vincent Chung, MD         
Cedars-Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Laura Sarmiento    310-423-4295    Laura.Sarmiento@cshs.org   
Principal Investigator: Nicholas Nissen, MD         
Sutter Institute for Medical Research Recruiting
Sacramento, California, United States, 95816
Contact: Clara Dunn    916-454-6931    dunncm@sutterhealth.org   
Principal Investigator: Stacy D'Andre, MD         
California Pacific Medical Center Recruiting
San Francisco, California, United States, 94115
Contact: Laurel Brechtel    415-600-1654    BrechtLa@cpmcri.org   
Principal Investigator: Ari Baron, MD         
United States, Connecticut
Stamford Hospital Recruiting
Stamford, Connecticut, United States, 06902
Contact: Ed Hatton    203-276-8447    EHatton@stamhealth.org   
Principal Investigator: Salvatore Del Prete, MD         
United States, Florida
Boca Raton Regional Hospital Recruiting
Boca Raton, Florida, United States, 33486
Contact: Sylvie Godbout, RN, BSN    561-955-4800    SGodbout@brrh.com   
Principal Investigator: Warren Brenner, MD         
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Alison Ivey    352-265-0680 ext 88411    aivey@ufl.edu   
Contact: Kevin Tormes    (352) 265-0680 ext 87617    ktormes@ufl.edu   
Principal Investigator: Thomas George, MD         
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Karen Blackburn, CCRC    305-243-0863    k.blackburn@med.miami.edu   
Principal Investigator: Peter Hosein, MD         
USF Tampa General Recruiting
Tampa, Florida, United States, 33606
Contact: Jerry Owens    813-844-4618    jowens@health.usf.edu   
Principal Investigator: Vic Velanovich, MD         
H. Lee Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Helen Jump    813-745-4834    Helen.Jump@moffitt.org   
Principal Investigator: Gregory Springett, MD         
United States, Illinois
Illinois Cancer Specialists Recruiting
Arlington Heights, Illinois, United States, 60005
Contact: Heather Lee    847-259-0624    Heather.lee@usoncology.com   
Principal Investigator: Rich Siegel, MD         
United States, Indiana
Indiana University Health Goshen Center for Cancer Care Recruiting
Goshen, Indiana, United States, 46526
Contact: Vanessa DePue    574-364-2649    vdepue@iuhealth.org   
Principal Investigator: Roderich Schwarz, MD, PhD         
Indiana University Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Lynne McCranor    317-278-4712    lmccrano@iupui.edu   
Contact: Matt Burns    317-278-8247    matburns@iupui.edu   
Principal Investigator: Romnee Clark, MD         
United States, Kansas
University of Kansas Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Ashley Shores    913-588-1897    ashores@kumc.edu   
Principal Investigator: Joaquina Baranda, MD         
United States, Michigan
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Dusty Kah    313-916-1074    dkah1@hfhs.org   
Principal Investigator: Kellie McFarlin, MD, FACS         
United States, Minnesota
Virginia Piper Cancer Institute Recruiting
Minneapolis, Minnesota, United States, 55407-3799
Contact: Lisa Albers    612-863-9466    lisa.albers@allina.com   
Principal Investigator: John Seng, MD         
United States, New York
Mount Sinai Medical Center Recruiting
New York, New York, United States, 10029
Contact: Prerna Chopra    212-241-4863    prerna.chopra@mountsinai.org   
Principal Investigator: Daniel Labow, MD         
United States, North Carolina
Wake Forest Baptist Health Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Jennifer MacLean    336-713-3539    jemaclea@wakehealth.edu   
Principal Investigator: Angela Alistar, MD         
United States, Ohio
The Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Hamida Umar    614-685-6406    Hamida.Umar@osumc.edu   
Principal Investigator: Tanios Bekaii-Saab, MD         
United States, Oklahoma
University of Oklahoma Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Melissa Yarbrough, RN    405-271-8001 ext 48340    melissa-yarbrough@ouhsc.edu   
Principal Investigator: Shubham Pant, MD         
United States, Oregon
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Brigitte Montgomery    503-494-8699    montgobr@ohsu.edu   
Principal Investigator: Gina Vaccaro, MD         
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Matthew Isenberg    215-503-2983    mxi195@jefferson.edu   
Principal Investigator: Harish Lavu, MD         
United States, Tennessee
University of Tennessee Medical Center Recruiting
Knoxville, Tennessee, United States, 37920
Contact: Shanna Overbey, RN, BSN    865-305-9773 ext 4    SOverbey@mc.utmck.edu   
Principal Investigator: Janakiraman Subramanian, MD         
United States, Texas
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Tyson Dudley    214-648-7031    tyson.dudley@utsouthwestern.edu   
Principal Investigator: John C. Mansour, MD         
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Glenn Wilson    713-798-3468    ggwilson@bcm.tmc.edu   
Contact: Carolyn Thibodeaux    713.798.4797    carolynt@bcm.edu   
Principal Investigator: Benjamin Musher, MD         
United States, Washington
University of Washington - Seattle Cancer Center Alliance Recruiting
Seattle, Washington, United States, 98109
Contact: Grace Gyurkey    206-288-7603    ggyurkey@seattlecca.org   
Principal Investigator: Andrew Coveler, MD         
United States, Wisconsin
Vince Lombardi Cancer Center Recruiting
Green Bay, Wisconsin, United States, 54311
Contact: Kate Newbanks, RN, BSN, OCN    920-288-4115    kate.newbanks@aurora.org   
Principal Investigator: Dhimant Patel, MD         
University of Wisconsin Recruiting
Madison, Wisconsin, United States, 53792
Contact: Carissa Amundson    608-265-1181    camund@uwcarbone.wisc.edu   
Contact: Kathryn Sklenar    (608) 263-9912    ksklenar@uwcarbone.wisc.edu   
Principal Investigator: Clifford Cho, MD         
Sponsors and Collaborators
NewLink Genetics Corporation
Investigators
Study Director: Nicholas N Vahanian, MD NewLink Genetics Corporation
  More Information

No publications provided

Responsible Party: NewLink Genetics Corporation
ClinicalTrials.gov Identifier: NCT01836432     History of Changes
Other Study ID Numbers: NLG0505, 1210-1195
Study First Received: April 17, 2013
Last Updated: July 1, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by NewLink Genetics Corporation:
Pancreatic Cancer
Immunotherapy
Vaccine Therapy

Additional relevant MeSH terms:
Neoplasms
Carcinoma
Pancreatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Fluorouracil
Gemcitabine
Capecitabine
Oxaliplatin
Irinotecan
Paclitaxel
Leucovorin
Levoleucovorin
Pancrelipase
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antimetabolites, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Vitamin B Complex

ClinicalTrials.gov processed this record on August 21, 2014